TT-00920

DRUG3 trials

Sponsors

TransThera Sciences (Nanjing), Inc.

Conditions

Healthy

Phase 1

Phase I, First-In-Human Study of TT-00920 in Healthy Subjects

CompletedNCT04364789

TransThera Sciences (Nanjing), Inc.Healthy

Start: 2020-02-05End: 2022-03-17Updated: 2023-02-27

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Dose of TT-00920 in Healthy Subjects

CompletedNCT05043792

TransThera Sciences (Nanjing), Inc.Healthy

Start: 2021-08-19End: 2021-11-30Updated: 2023-11-18

A Phase 1 Study of TT-00920 in Healthy Subjects

CompletedNCT05355129

TransThera Sciences (Nanjing), Inc.Healthy

Start: 2021-11-03End: 2022-06-06Updated: 2023-02-27

Related Papers

Abstract 13810: TT-00920, a Clinical Stage Novel Phosphodiesterase 9 Inhibitor, Protects Against Heart Failure in a Rat Model of Myocardial Infarction

Circulation2020-11-172 citations